These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
106 related articles for article (PubMed ID: 8826617)
1. Metoclopramide as a modulator of cisplatin: effects on pharmacokinetcs and cisplatin-DNA adducts in tumor and normal tissue. Johnsson A; Kjellén E; Wennerberg J; Pero R Anticancer Drugs; 1996 Jun; 7(4):483-8. PubMed ID: 8826617 [TBL] [Abstract][Full Text] [Related]
2. Expression of GADD153 in tumor cells and stromal cells from xenografted tumors in nude mice treated with cisplatin: correlations with cisplatin-DNA adducts. Johnsson A; Strand C; Los G Cancer Chemother Pharmacol; 1999; 43(4):348-52. PubMed ID: 10071988 [TBL] [Abstract][Full Text] [Related]
3. Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck. Kjellén E; Wennerberg J; Pero R Br J Cancer; 1989 Feb; 59(2):247-50. PubMed ID: 2930689 [TBL] [Abstract][Full Text] [Related]
4. Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck. Lybak S; Wennerberg J; Kjellén E; Pero RW Anticancer Drugs; 1991 Aug; 2(4):375-82. PubMed ID: 1797194 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593 [TBL] [Abstract][Full Text] [Related]
6. A topographic study on the distribution of cisplatin in xenografted tumors on nude mice. Johnsson A; Cavallin-Stahl E Anticancer Drugs; 1996 Jan; 7(1):70-7. PubMed ID: 8742101 [TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of cisplatin in human head and neck cancer: correlation between platinum content, DNA adduct levels and drug sensitivity in vitro and in vivo. Welters MJ; Fichtinger-Schepman AM; Baan RA; Jacobs-Bergmans AJ; Kegel A; van der Vijgh WJ; Braakhuis BJ Br J Cancer; 1999 Jan; 79(1):82-8. PubMed ID: 10408697 [TBL] [Abstract][Full Text] [Related]
8. Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck. Lybak S; Kjellén E; Wennerberg J; Pero R Int J Radiat Oncol Biol Phys; 1990 Dec; 19(6):1419-24. PubMed ID: 2262366 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of cisplatin with and without amifostine in tumour-bearing nude mice. Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ Eur J Cancer; 1998 Feb; 34(3):412-6. PubMed ID: 9640232 [TBL] [Abstract][Full Text] [Related]
10. Biochemical modulation of chemotherapy and radiotherapy in head and neck cancer. Wennerberg J; Kjellén E; Lybak S; Rydell R; Pero R Anticancer Res; 1993; 13(6B):2501-6. PubMed ID: 8135490 [TBL] [Abstract][Full Text] [Related]
11. Amifostine as a protector against cisplatin-induced toxicity in nude mice. Johnsson A; Wennerberg J Acta Oncol; 1999; 38(2):247-53. PubMed ID: 10227448 [TBL] [Abstract][Full Text] [Related]
12. Circadian variations in cell cycle phase distribution in a squamous cell carcinoma xenograft; effects of cisplatin and fluorouracil treatment. Rydell R; Wennerberg J; Willen R In Vivo; 1990; 4(6):385-9. PubMed ID: 2103378 [TBL] [Abstract][Full Text] [Related]
13. Effects of intralesional injection of cisplatin on squamous cell carcinoma and normal tissue of mice. Landrito JE; Yoshiga K; Sakurai K; Takada K Anticancer Res; 1994; 14(1A):113-8. PubMed ID: 8166436 [TBL] [Abstract][Full Text] [Related]
14. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT). Hoebers FJ; Pluim D; Verheij M; Balm AJ; Bartelink H; Schellens JH; Begg AC Int J Cancer; 2006 Aug; 119(4):750-6. PubMed ID: 16550603 [TBL] [Abstract][Full Text] [Related]
15. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534 [TBL] [Abstract][Full Text] [Related]
16. Effects of amifostine on cisplatin induced DNA adduct formation and toxicity in malignant glioma and normal tissues in rat. Bergström P; Johnsson A; Bergenheim T; Henriksson R J Neurooncol; 1999 Mar; 42(1):13-21. PubMed ID: 10360475 [TBL] [Abstract][Full Text] [Related]
17. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines. Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528 [TBL] [Abstract][Full Text] [Related]
18. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells. O'Neill CF; Hunakova L; Kelland LR Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899 [TBL] [Abstract][Full Text] [Related]
19. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Zamboni WC; Gervais AC; Egorin MJ; Schellens JH; Zuhowski EG; Pluim D; Joseph E; Hamburger DR; Working PK; Colbern G; Tonda ME; Potter DM; Eiseman JL Cancer Chemother Pharmacol; 2004 Apr; 53(4):329-36. PubMed ID: 14673619 [TBL] [Abstract][Full Text] [Related]
20. Evaluation of a method for quantitative immunohistochemical analysis of cisplatin-DNA adducts in tissues from nude mice. Johnsson A; Olsson C; Anderson H; Cavallin-Ståhl E Cytometry; 1994 Oct; 17(2):142-50. PubMed ID: 7835164 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]